Clinical trial
Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures
NCT00384358 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00384358 |
|---|---|
| Title | Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures |
| Official title | A Phase 2, Multicenter, Single-Blind, Randomized, Stratified, Standard-Of-Care Controlled, Feasibility And Safety Study Of rhBMP-2/CPM As An Adjuvant Therapy For Fractures Of The Proximal Femur |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fractures |
| Intervention type | Drug, Other |
| Interventions | rhBMP-2/CPM, surgical intervention alone |
| Enrollment | 108 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Oct 6, 2006 |
| Last update posted | Feb 28, 2013 |
| Countries | Australia, Canada, Finland, France, Germany, Hungary, Norway, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: